Peers of Inhibrx Biosciences Inc (INBX)
Side-by-side comparison
Health Care · Biotechnology
Enterprise value divided by trailing twelve-month revenue. A capital-structure-neutral sales valuation metric.
Latest EV/Sales
1083.31x
As of Jun 29, 2026
Beyond EV/Sales, the valuation view includes forward multiples, EV ratios, cash flow yields, and multi-year chart history for further research.
| Date | EV/Sales |
|---|---|
| Jun 29, 2026 | 1083.31x |
| Jun 26, 2026 | 1075.56x |
| Jun 25, 2026 | 1081.18x |
| Jun 24, 2026 | 1079.27x |
| Jun 23, 2026 | 1054.21x |
| Jun 22, 2026 | 1058.59x |
| Jun 18, 2026 | 1055.78x |
| Jun 17, 2026 | 1068.70x |
EV/Sales = Enterprise Value / Revenue (TTM). Enterprise Value = Market Cap + Total Debt − (Cash & Short-Term Investments + Long-Term Investments).
EV/Sales is particularly useful in M&A analysis and for companies with significant debt.
Read the general EV/Sales definition, formula, and analyst usage guide.
EV/Sales guideInformational research only; not personalized advice. Values reflect the latest available data on Chartloom and may differ from other sources.
Side-by-side comparison